Gilead Sciences (GILD) Revenue (2009 - 2025)

Gilead Sciences has reported Revenue for 17 years, with the latest figure at $29.4 billion in FY2025.

• For the quarter ending Q1 2026, Revenue rose 4.39% year-over-year to $7.0 billion; the trailing twelve-month figure through Mar 2026 stood at $29.7 billion (up 3.48% YoY), and the FY2025 full-year result was $29.4 billion, up 2.4% from the prior year.
• Revenue for FY2025 stood at $29.4 billion, up from $28.8 billion in the prior year.
• The five-year high for Revenue was $29.4 billion in FY2025, with the low at $27.1 billion in FY2023.
• Historically, Revenue has averaged $28.0 billion across 5 years, with a median of $27.3 billion in 2021.
• Annual changes were most pronounced in 2021 — Revenue increased 10.6% — and 2023, when it retreated 0.6%.
• Gilead Sciences' Revenue stood at $27.3 billion in 2021, then slipped by 0.09% to $27.3 billion in 2022, then retreated by 0.6% to $27.1 billion in 2023, then increased by 6.04% to $28.8 billion in 2024, then increased by 2.4% to $29.4 billion in 2025.
• The last three Revenue figures came in at $29.4 billion (FY2025), $28.8 billion (FY2024), and $27.1 billion (FY2023), per Business Quant data.